FIELD: medicine.
SUBSTANCE: invention refers to application of peptides of antagonistic action in the relation bradykinin, suitable for medical products for prevention and treatment of diseases influenced by increased activity of matrix metalloproteinase. They are degenerative arthropathies, e.g., osteoarthrosis, spondylosis, as well as cartilage atrophy caused by joit injury or prolonged joint immovability following meniscus or patella damage or ligamentous rupture.
EFFECT: invention provides more effective brake of matrix splitting in comparison with only MMP inhibition of already released or formed tissues.
3 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NEW NPR-B AGONISTS | 2010 |
|
RU2636738C2 |
| PEPTIDES AND THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS | 1992 |
|
RU2083586C1 |
| PEPTIDES, METHOD OF THEIR SYNTHESIS, AGENT SHOWING BRADYKININ-ANTAGONISTIC ACTIVITY | 1993 |
|
RU2109747C1 |
| NOVEL NRP-B AGONISTS | 2010 |
|
RU2557290C2 |
| METASTIN DERIVATIVES AND USE THEREOF | 2007 |
|
RU2454425C2 |
| DIPEPTIDE LINKED MEDICINAL AGENTS | 2009 |
|
RU2578591C2 |
| NEW FIVE-MEMBER HETEROCYCLES, THEIR PREPARING, THEIR APPLYING AND PHARMACEUTICAL PREPARATIONS COMPRISING THEREOF | 1998 |
|
RU2240326C2 |
| α-CYCLODEXTRIN-BASE PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF ANALOGS OF RELEASING-HORMONE OF LUTEINIZING HORMONE (LH-RH) | 1999 |
|
RU2214270C2 |
| ANTIBODY-DRUG CONJUGATES INCLUDING ANTIBODY AGAINST HUMAN DLK1 AND THEIR USE | 2020 |
|
RU2801630C2 |
| CALICHEAMICIN DERIVATIVES AND THEIR ANTIBODY-DRUG CONJUGATES | 2018 |
|
RU2732568C1 |
